Ipca Laboratories Q2 FY27 Results Analysis: PAT Jumps 33%, EBITDA Margin Expands 128 bps (IPCALAB)

Cofacto Research Published November 05, 2026 4 min read

Positive

Ipca Laboratories Ltd's Q2 FY27 numbers came in strong, with revenue of Rs. 2,909.94 Cr (+13.79% YoY) and PAT growth of +32.77% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details

Results date	November 05, 2026
Revenue (Q2)	Rs. 2,909.94 Cr (+13.79% YoY)
PAT (Q2)	Rs. 375.13 Cr (+32.77% YoY)
EBITDA margin	22.97% (+128 bps YoY)
EPS (Q2)	Rs. 14.79 (+23.81% YoY)

Quarter Snapshot

IPCALAB delivered revenue growth of 13.79% YoY with EBITDA margin up 128 bps to 22.97% and owners' PAT up 32.77%, tracking on or ahead of every derivable FY27 guidance metric including the ~23% margin target management had cautioned could peak in Q2. The main blemishes are cash conversion (H1 CFO/PAT 0.738x) from a receivables and inventory build, a 6.94% decline in export APIs, and subsidiaries' 4.50% top-line growth; H2 requires only ~11-15% revenue growth and a ~23.08% margin to meet full-year guidance.

Q2 FY27 Expectations vs Results

Driver	Expected before results	What happened	Verdict
Revenue vs raised 14–16% guide	"revenue tailwinds intact against a tougher base"	H1 +17.09%; Q2 +13.79%	Played out
Q2 margin hold (~23% guide) — "the contested question" vs freight/materials	margin under visible pressure	Q2 22.97% (+128 bps YoY, above Q1's 22.88%)	Played out
FX tailwind persisting "at least the next two quarters"	rupee in Rs.95–96 band all quarter	Filing silent on FX narrative; forex line favourable	Partially
Institutional run-rate ex-slip vs Rs.260–300 Cr	test vs ~Rs.72 Cr underlying	Q2 Rs.115.76 Cr; H1 Rs.235.51 Cr	Played out
Unichem Q2 print tests held guidance	12–13% margin band at risk	Unichem-specific data not disclosed; subsidiaries' aggregate +4.50%	Not observable
Domestic share-lag risk vs a 12–13.5% IPM market	"second consecutive quarter of share lag is the risk"	Domestic formulations +13.57% Q2 (above the cited IPM range); IQVIA share not in filing	Partially
Pre-registered one-time items	none pre-flagged	Filing's Rs.24.26 Cr provision confirmed and normalized	Confirmed from filing

Read our full results preview.

Management Guidance vs Delivery

What management said	Where	What happened	Verdict
Consolidated revenue growth 14–16% FY27	Q1 FY27 earnings call (raised from 12–13%)	H1 +17.09%; Q2 +13.79%	On Track
Consolidated EBITDA margin ~23% FY27 (company basis)	Q1 FY27 earnings call (raised from 22%)	Q2 22.97%; H1 22.92%	On Track
Domestic branded ~12% growth FY27	Q1 FY27 earnings call	Q2 +13.57%; H1 +13.10%	On Track
Exports 12–13% growth (INR) FY27	Q1 FY27 earnings call	Q2 standalone export income +16.96% (Rs.951.39 Cr); H1 +24.65% (Rs.1,886.78 Cr)	On Track
Institutional Rs.260–300 Cr FY27	Q1 FY27 earnings call	H1 Rs.235.51 Cr already near the full-year band's lower half	On Track
Capex Rs.700–800 Cr FY27	Q1 FY27 earnings call	H1 Rs.442.81 Cr	On Track
LT debt ~Rs.70 Cr term loan at FY27-end	Q1 FY27 earnings call	Non-current borrowings Rs.67.35 Cr at 30 Sep 2026	On Track
"Standalone Net Profit… up 27%"; "Consolidated Net Profit… up 33%" (after exceptionals)	Q2/H1 FY27 press release	387.29 (+27.09%) and 375.13 (+32.77%)	Confirmed
Q2 could be a peak-margin quarter (domestic slows in H2)	Q2 FY26 earnings call	Q2 FY27 margin 22.97% > Q1's 22.88%; caution not borne out this quarter — for now	Confirmed the opposite
Margin improvement of ~1% FY27 / ~23% level	Q4 & Q1 FY27 calls	+128 bps YoY already in H1	On Track

Key Investment Insights

Key Positives

Consolidated revenue grew 13.79% YoY to Rs.2,909.94 Cr; H1 revenue grew 17.09% to Rs.5,698.04 Cr
Management-basis EBITDA margin expanded 128 bps YoY to 22.97%, above Q1 FY27's 22.88% and against management's ~23% FY27 guidance
Consolidated owners' PAT grew 32.77% YoY to Rs.375.13 Cr; normalized PAT grew 20.86%
Formulations grew 19.73% YoY; export institutional formulations +45.27% (H1 Rs.235.51 Cr, +71.32%) and domestic APIs +56.12%
Standalone revenue grew 16.85% YoY, faster than subsidiaries' aggregate +4.50% — growth is parent-led
Finance costs fell 35.90% YoY to Rs.12.57 Cr; borrowings fell Rs.77.69 Cr in H1 to Rs.626.25 Cr with a net cash position of Rs.484.66 Cr
H2 revenue needed to meet FY27 guidance is only +10.83% to +14.87% YoY, and H2 margin needed is ~23.08% — both on track
FCF of Rs.130.51 Cr (CFO Rs.573.32 Cr less capex Rs.442.81 Cr) despite working-capital build

Risk Factors

H1 CFO/PAT of 0.738x and CFO/EBITDA of 0.439x, driven by a Rs.206.78 Cr inventory build and Rs.364.57 Cr receivables increase
Trade receivables grew 18.90% and inventories Rs.206.78 Cr in six months, both outpacing 17.09% H1 revenue growth
Export APIs declined 6.94% YoY — the only declining revenue line
Subsidiaries' aggregate revenue grew only 4.50% YoY; consolidated owners' PAT sat Rs.12.16 Cr below standalone PAT due to NCI swing and associates
Other expenses grew 16.34% YoY, faster than revenue, consistent with flagged freight/logistics cost pressure
Effective tax rate rose ~84 bps YoY to 28.44%, with total tax +43.97% vs PBT +39.73%